secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2022-11-07T23:59:59+00:00
Accession:  0000950170-22-022628
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte reports positive VAX-24 Phase 1/2 data; Q3 net loss $57.9M, cash $366.2M plus $650.7M offering
--------------------------------------------------------------------------------

- Q3 net loss $57.9M (vs $26.6M YoY); R&D $47.7M (up from $20.4M) on Phase 3/IND activities.
- Cash $366.2M at Sep 30, plus ~$650.7M net from Oct follow-on offering.
- VAX-24 Phase 1/2 met endpoints; at 2.2mcg dose, non-inferiority for all 20 PCV20 serotypes, 16 higher, 4 superior.
- Expect VAX-24 Phase 2 data in 65+ in H1 2023; infant IND in H1 2023; VAX-XP IND in H2 2023.
- Appointed Mark Wiggins as CBO and Jakub Simon as CMO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000095017022022628/0000950170-22-022628-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000095017022022628/pcvx-20221107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-022628

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer